Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients

Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients

Publication Date: March 10, 2022


Abstract Image

A critical unmet need for advanced prostate cancer (PCa) patients is optimizing systemic treatments to maximize the benefit for individuals. The response of patients with metastatic castration-resistant prostate cancer (mCRPC) to androgen receptor (AR)-directed hormonal treatments (i.e., enzalutamide and abiraterone) is mediated by the expression of a molecular variant of the androgen receptor called androgen receptor variant 7 (AR-V7). Detection and measurement of AR-V7 in mCRPC patients will lead to more informed PCa treatment. Herein, we demonstrate a quantitative nanoparticle-enhanced sandwich antibody assay for the successful ex vivo measurement of AR-V7 protein in serum from mCRPC patients. The nanoparticles are constructed as extrinsic Raman spectroscopy labels (ERLs), and surface-enhanced Raman spectroscopy (SERS) is used for assay readout. Our approach does not require specialized specimen collection materials, circulating tumor cell enrichment, or pretreatment of serum. Calibration of our assay is accomplished by expressing AR-V7 in an appropriate cell line as AR-V7 is not commercially available. We demonstrate a linear calibration curve from cell lysate and correlate lysate protein with mRNA from cultured prostate cancer cells. Finally, we demonstrate a novel pilot-scale application for clinical use by quantitatively measuring AR-V7 in serum of seven advanced PCa patients. Distinct separation of PCa patients by AR-V7 status (positive or negative) was observed. Together, the presence and amount of AR-V7 in serum offer predictive and prognostic value to inform selection between two classes of systemic treatments (i.e., hormones or taxanes). Triaging patients that are AR-V7-positive to other systemic treatments (e.g., taxane-based chemotherapy) can improve progression-free survival and overall survival.

Cite this: ACS Sens. 2022

Falling Walls Venture – Berlin 2018

Congratulations to John Lewis and Nanostics for winning an entry into the highly competitive and prestigious Falling Walls Venture Conference in Berlin, November 8-9, 2018!

Five presenters pitched their healthcare-related ideas and innovations to a panel of tech and business-savvy judges and a large audience on Aug 29, 2018, at the University of Alberta in a high-stakes “TEDTalk” meets “Dragon’s Den” style. The competition was tough but John Lewis edged out the fellow contenders to win a chance to pitch a 5-minute talk on Nanostics’ high-accuracy prostate cancer diagnostic reflex test: ClarityDX Prostate.

John talked with Mark Connolly from the CBC Edmonton Morning show on September 4 about the Falling Walls competition and what he is preparing for this November.

Good luck to John Lewis at the Falling Walls Finale in Berlin!

John Lewis wins an entry to Falling Walls Berlin!

- Perrin Beatty